Amphastar Pharma (AMPH) Tops Q4 EPS by 2c

Amphastar Pharma (NASDAQ: AMPH) reported Q4 EPS of $0.13, $0.02 better than the analyst estimate of $0.11. Revenue for the quarter came in at $89.7 million versus the consensus estimate of $78.18 million.

For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Pfizer lung cancer drug misses survival goal in Phase 3 trial
• KeyBanc Downgrades Primoris Services Corporation (PRIM) to Sector Weight